3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
64
HER2-positive Breast Cancer
11
Carcinoma, Non-Small-Cell Lung
6
HER2 Positive Metastatic Breast Cancer
4
Breast Diseases
4
Brain Neoplasms
4
HER2 Positive Breast Cancer
3
Advanced Breast Cancer
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
HER2-positive Metastatic Breast Cancer
2
Colorectal Neoplasms
2
Breast Cancer Invasive
2
Breast Cancer Female
2
Solid Tumor
1
Salivary Gland Neoplasms
1
Rare Tumour
1
Rare Tumor
1
Pathologic Complete Response
1
Non-squamous NSCLC
1
Non Small Cell Lung
1
Neoplasm Metastasis
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Metastatic Breast Cancer in the Brain
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-expressing Advanced Solid Tumors
1
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
1
HER2+ Early or Locally Advanced Breast Cancer
1
Interventions
pembrolizumab
160
Carboplatin
143
Paclitaxel
125
Cyclophosphamide
93
130-nm albumin-bound paclitaxel
66
Capecitabine
63
Gemcitabine
54
Doxorubicin
49
Albumin-Bound Paclitaxel
45
Taxes
42
atezolizumab
40
Cisplatin
37
Nivolumab
34
sacituzumab govitecan
32
olaparib
32
Epirubicin
32
Docetaxel
28
eribulin
27
Specimen Handling
26
Bevacizumab
26
durvalumab
25
camrelizumab
23
Drug Therapy
22
Biopsy
22
Magnetic Resonance Spectroscopy
21
toripalimab
18
Radiotherapy
17
spartalizumab
16
Everolimus
15
fludarabine
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Triple Negative Breast Neoplasms
×
pyrotinib
×
Clear all
NCT05582499
2025-08-22
FASCINATE-N
Fudan University
Phase 2
Recruiting
716 enrolled
NCT03805399
2022-08-10
FUTURE
Fudan University
Phase 1/2
Unknown
140 enrolled